MET and non-small cell lung carcinoma: Based on the results of this study, in 2018 the FDA granted breakthrough therapy designation for crizotinib for the treatment of patients with NSCLC with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy (www.fda.gov accessed on 14 May 2023).